Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
Other Sizes |
|
Purity: ≥98%
Myricetin (Cannabiscetin), a naturally occurring flavonoid with antioxidant and anti-tumor properties, is a novel inhibitor of MEK1 activity and transformation of JB6 P+ mouse epidermal cells. Additionally, it inhibits PI3Kγ with Kd of 0.17 μM. Many grapes, berries, fruits, vegetables, herbs, and other plants contain the flavonoid myricetin, also known as cannabiscetin, which has anti-tumor and antioxidant properties.
Targets |
MEK1; PI3Kγ (Kd = 0.17 μM)
|
---|---|
ln Vitro |
Myricetin(Cannabiscetin) is a flavonoid with antioxidant and anti-tumor properties that can be found in a variety of plants, including grapes, berries, fruits, vegetables, herbs, and other plants. The antioxidant properties of myricetin. High concentrations of myricetin may modify LDL cholesterol in a way that increases uptake by white blood cells, according to in vitro research. [1] According to studies, a high myricetin intake lowers the risk of pancreatic and prostate cancer. [2] [3]
|
ln Vivo |
Orthotopic tumor kinases treated with myricetin exhibit regression and reduced proliferation [2]. ADP, arachidonic acid, collagen, PAF, and 14%, 26%, 5%, and 49% of rabbits were found to have tumors localized in rabbits subjected to 150 μM myricetin, respectively [5].
|
Cell Assay |
Myricetin (12.5-200 μM) is used to treat pancreatic cancer cells (MIA PaCa-2, Panc-1, or S2-013) or healthy pancreatic ductal cells (PDCs). Dojindo Cell Counting Kit-8 is used to assess cell viability. 1×104 cells are seeded into each well of a 96-well plate, and the cells are left to adhere for the night. Ten microliters of the tetrazolium substrate are added to each well of the plate after myricetin treatments at various concentrations were given for 24 hours. The absorbance at 450 nm is measured after plates have been incubated at 37°C for an hour.
|
Animal Protocol |
Mice: For 35 days (MIA PaCa-2 model) or 18 days (S2-013 model), mice receive daily intraperitoneal injections of myricetin (30 mg/kg in the MIA PaCa-2 model and 50 mg/kg in the S2-013 model) or a vehicle (DMSO). To track tumor growth, ultrasound measurements are taken on a regular basis. At the conclusion of the in vivo experiment, the tumor volume and size are calculated[2].
|
References |
[1]. Semwal DK, et al. Myricetin: A Dietary Molecule with Diverse Biological Activities. Nutrients. 2016 Feb 16;8(2):90.
[2]. Phillips PA, et al. Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of thephosphatidylinositol 3-kinase (PI3K) signaling pathway. Cancer Lett. 2011 Sep 28;308(2):181-8. [3]. Xu Y, et al. Myricetin induces apoptosis via endoplasmic reticulum stress and DNA double-strand breaks in human ovarian cancer cells. Mol Med Rep. 2016 Mar;13(3):2094-100. [4]. Jinwal UK, et al. Chemical Manipulation of Hsp70 ATPase Activity Regulates Tau Stability. J Neurosci. 2009 Sep 30;29(39):12079-88. [5]. Tzeng SH, et al. Inhibition of platelet aggregation by some flavonoids. Thromb Res. 1991 Oct 1;64(1):91-100 |
Molecular Formula |
C15H10O8
|
|
---|---|---|
Molecular Weight |
318.24
|
|
Exact Mass |
318.04
|
|
Elemental Analysis |
C, 56.61; H, 3.17; O, 40.22
|
|
CAS # |
529-44-2
|
|
Related CAS # |
Dihydromyricetin;27200-12-0;Myricetin-13C3
|
|
Appearance |
Solid powder
|
|
SMILES |
C1=C(C=C(C(=C1O)O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O
|
|
InChi Key |
IKMDFBPHZNJCSN-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C15H10O8/c16-6-3-7(17)11-10(4-6)23-15(14(22)13(11)21)5-1-8(18)12(20)9(19)2-5/h1-4,16-20,22H
|
|
Chemical Name |
3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.54 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.54 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 4% DMSO +30%PEG 300 +ddH2O: 5mg/mL |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.1423 mL | 15.7114 mL | 31.4228 mL | |
5 mM | 0.6285 mL | 3.1423 mL | 6.2846 mL | |
10 mM | 0.3142 mL | 1.5711 mL | 3.1423 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Chemical structures of ( A ) resveratrol, ( B ) myricetin and ( C ) PD098059 and cytotoxic effects of ( D ) myricetin or ( E ) resveratrol on JB6 P+ cells. Carcinogenesis . 2007 Sep;28(9):1918-27 td> |
Comparison of the effect of myricetin or resveratrol on TPA- or EGF-induced neoplastic transformation of JB6 P+ cells. Carcinogenesis . 2007 Sep;28(9):1918-27 td> |
Comparison of the effect of myricetin or resveratrol on TPA- or EGF-induced AP-1, c-fos , MEK1 or ERK2 activation. Carcinogenesis . 2007 Sep;28(9):1918-27 td> |
Effect of myricetin on TPA- or EGF-induced phosphorylation of ERK, p90RSK or JNK in JB6 P+ cells. Carcinogenesis . 2007 Sep;28(9):1918-27 td> |
Comparison of the effect of myricetin, resveratrol or PD098059 on H-Ras-induced cell transformation. Carcinogenesis . 2007 Sep;28(9):1918-27 td> |
Effect of myricetin on pancreatic cancer cell (A) or normal pancreatic ductal cell (B) viability. Cancer Lett . 2011 Sep 28;308(2):181-8. td> |
Myricetin induces apoptosis in pancreatic cancer cells. Cancer Lett . 2011 Sep 28;308(2):181-8. td> |
Effect of myricetin on signaling proteins in pancreatic cancer cells. Cancer Lett . 2011 Sep 28;308(2):181-8. td> |
Myricetin inhibits pancreatic tumor growth in vivo. Cancer Lett . 2011 Sep 28;308(2):181-8. td> |